138 related articles for article (PubMed ID: 33664435)
1. Market concentration of new antibiotic sales.
Rahman S; Lindahl O; Morel CM; Hollis A
J Antibiot (Tokyo); 2021 Jun; 74(6):421-423. PubMed ID: 33664435
[TBL] [Abstract][Full Text] [Related]
2. Learning from our mistakes: using key opportunities to remove the perverse incentives that help drive antibiotic resistance.
Edwards SE; Morel CM
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):685-692. PubMed ID: 31847613
[No Abstract] [Full Text] [Related]
3. Introduction and geographic availability of new antibiotics approved between 1999 and 2014.
Kållberg C; Årdal C; Salvesen Blix H; Klein E; M Martinez E; Lindbæk M; Outterson K; Røttingen JA; Laxminarayan R
PLoS One; 2018; 13(10):e0205166. PubMed ID: 30325963
[TBL] [Abstract][Full Text] [Related]
4. Systems, not pills: The options market for antibiotics seeks to rejuvenate the antibiotic pipeline.
Brogan DM; Mossialos E
Soc Sci Med; 2016 Feb; 151():167-72. PubMed ID: 26808335
[TBL] [Abstract][Full Text] [Related]
5. Evaluating for-profit public benefit corporations as an additional structure for antibiotic development and commercialization.
Outterson K; Rex JH
Transl Res; 2020 Jun; 220():182-190. PubMed ID: 32165059
[TBL] [Abstract][Full Text] [Related]
6. The distribution of sales revenues from pharmaceutical innovation.
Grabowski HG; Vernon J
Pharmacoeconomics; 2000; 18 Suppl 1():21-32. PubMed ID: 11151306
[TBL] [Abstract][Full Text] [Related]
7. Repairing the broken market for antibiotic innovation.
Outterson K; Powers JH; Daniel GW; McClellan MB
Health Aff (Millwood); 2015 Feb; 34(2):277-85. PubMed ID: 25646108
[TBL] [Abstract][Full Text] [Related]
8. Outlook: the profit problem in antibiotic R&D.
Nathan C; Goldberg FM
Nat Rev Drug Discov; 2005 Nov; 4(11):887-91. PubMed ID: 16247440
[TBL] [Abstract][Full Text] [Related]
9. Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model.
Brogan DM; Mossialos E
Global Health; 2013 Nov; 9():58. PubMed ID: 24199835
[TBL] [Abstract][Full Text] [Related]
10. A Comparative Study of the Market Configuration of the Japanese Pharmaceutical Market Using the Gini Coefficient and Herfindahl-Hirschman Index.
Shibata S; Fukumoto D; Suzuki T; Ozaki K
Ther Innov Regul Sci; 2020 Sep; 54(5):1047-1055. PubMed ID: 31989539
[TBL] [Abstract][Full Text] [Related]
11. Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach.
Rex JH; Outterson K
Lancet Infect Dis; 2016 Apr; 16(4):500-5. PubMed ID: 27036356
[TBL] [Abstract][Full Text] [Related]
12. The relationship between pharmacy benefit managers (PBMs) and the cost of therapies in the US pharmaceutical market: A policy primer for clinicians.
Schulman KA; Dabora M
Am Heart J; 2018 Dec; 206():113-122. PubMed ID: 30447542
[TBL] [Abstract][Full Text] [Related]
13. Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry.
DiMasi JA; Hansen RW; Grabowski HG; Lasagna L
Pharmacoeconomics; 1995 Feb; 7(2):152-69. PubMed ID: 10155302
[TBL] [Abstract][Full Text] [Related]
14. Progress towards antibiotic use targets in eight high-income countries.
Simmons B; Ariyoshi K; Ohmagari N; Pulcini C; Huttner B; Gandra S; Satta G; Moja L; Sharland M; Magrini N; Miraldo M; Cooke G
Bull World Health Organ; 2021 Aug; 99(8):550-561. PubMed ID: 34354310
[TBL] [Abstract][Full Text] [Related]
15. Implications of "market baskets," a pharmaceutical marketing practice.
Rhame FS
JAMA; 1999 Sep 22-29; 282(12):1134. PubMed ID: 10501115
[No Abstract] [Full Text] [Related]
16. Impact of antibiotic restrictions: the pharmaceutical perspective.
Power E
Clin Microbiol Infect; 2006 Aug; 12 Suppl 5():25-34. PubMed ID: 16827822
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies.
Tay-Teo K; Ilbawi A; Hill SR
JAMA Netw Open; 2019 Jan; 2(1):e186875. PubMed ID: 30644967
[TBL] [Abstract][Full Text] [Related]
18. Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness.
Berndt ER; Glennerster R; Kremer MR; Lee J; Levine R; Weizsäcker G; Williams H
Health Econ; 2007 May; 16(5):491-511. PubMed ID: 17013993
[TBL] [Abstract][Full Text] [Related]
19. The critical impact of time discounting on economic incentives to overcome the antibiotic market failure.
Spellberg B; Sharma P; Rex JH
Nat Rev Drug Discov; 2012 Feb; 11(2):168. PubMed ID: 22293569
[No Abstract] [Full Text] [Related]
20. Economic return of clinical trials performed under the pediatric exclusivity program.
Li JS; Eisenstein EL; Grabowski HG; Reid ED; Mangum B; Schulman KA; Goldsmith JV; Murphy MD; Califf RM; Benjamin DK
JAMA; 2007 Feb; 297(5):480-8. PubMed ID: 17284698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
